Tuberculosis Vaccine Candidate to Prevent Disease Enters Clinical Testing

August 22nd, 2012|Press Releases|

Seattle, WA | August 22, 2012 Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI’s novel tuberculosis vaccine candidate, ID93 + GLA-SE. The Phase I clinical trial will assess [...]

IDRI and Medicago Announce FDA Authorization to Initiate a Phase 1 Clinical Trial for an H5N1 Vaccine with GLA Adjuvant

August 16th, 2012|Press Releases|

Seattle, WA | August 16, 2012 The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical [...]

IDRI Receives $3.7 Million Grant for TB Drug Discovery

July 25th, 2012|Press Releases|

Seattle, WA | July 25, 2012 IDRI's drug discovery efforts continue to grow with a recently awarded five-year grant for $3.7 million from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The [...]

Seattle Center’s Next 50

July 5th, 2012|Events|

Seattle, WA | July 5, 2012 As the Seattle Center celebrates 50 years since the 1962 World’s Fair, we, at IDRI, are thrilled to be sharing our innovations and vision of Global Heath for the “Next 50 years? with [...]

IDRI Expands Board, Adding Additional International Expertise

July 2nd, 2012|Press Releases|

Seattle, WA | July 2, 2012 The Infectious Disease Research Institute (IDRI) continues to expand its Board of Directors, comprised of international leaders in industry and academia, with the recent addition of Massimo Radaelli, Ph.D., who has 25 years [...]

IDRI Signs Lease with Alexandria Real Estate Equities, Inc. for New Seattle Headquarters

May 30th, 2012|Press Releases|

Seattle, WA | May 30, 2012 The Infectious Disease Research Institute (IDRI) has officially signed a new lease in Seattle’s South Lake Union neighborhood with long-time real estate partner Alexandria Real Estate Equities, Inc.  IDRI intends to relocate in [...]

IDRI Quest for Leprosy Vaccine Closer to Reality with Help of Million Dollar Grant

March 8th, 2012|Press Releases|

Seattle, WA | March 8, 2012 Leprosy, otherwise referred to as Hansen's Disease, is one of the most ancient diseases known to humans. Although the World Health Organization declared leprosy to be under control in many previously endemic countries, [...]

First Vaccine Against Fatal Visceral Leishmaniasis Enters Clinical Trial

February 22nd, 2012|Press Releases|

Seattle, WA | February 22, 2012 The first clinical trial of a new vaccine for visceral leishmaniasis (VL) has been launched by the Infectious Disease Research Institute (IDRI), a Seattle-based nonprofit that develops products to prevent, detect, and treat [...]

IDRI Awarded Additional Funds for Novel TB Drugs

January 11th, 2012|Press Releases|

Seattle, WA | January 11, 2012 The Infectious Disease Research Institute (IDRI) announced today the receipt of supplemental funds from the Bill & Melinda Gates Foundation, totaling over half a million dollars to augment the multi-million dollar award made [...]

Human trials initiated for new HIV vaccine

December 21st, 2011|Press Releases|

Seattle, WA | December 21, 2011 In the first clinical trial of an injectable vaccine containing trimeric HIV envelope protein (gp140) relevant to the predominant strain of HIV in Africa, researchers from four UK academic centers (St George's University [...]

Load More